早期肺腺癌CT定义磨玻璃影的预后价值:单中心研究与Meta分析
该单中心回顾性队列纳入612例临床I期肺腺癌患者,多因素Cox回归显示实性结节(无磨玻璃影)与更差的无复发生存(校正HR 1.98)和肺癌特异性生存(校正HR 1.937)相关;Meta分析纳入13项研究共12080例患者,实性结节汇总HR对总生存为2.13、无复发生存为2.45、无复发生存期为2.50,结论认为早期肺腺癌无磨玻璃影与术后生存更差相关。
要点
- 早期肺腺癌术前CT表现为实性结节(无磨玻璃影)与术后无复发生存和肺癌特异性生存更差相关。
- 单中心队列校正HR:无复发生存1.98(95%CI 1.17-3.51,p=0.01),肺癌特异性生存1.937(95%CI 1.002-4.065,p=0.049)。
- Meta分析汇总HR:总生存2.13(95%CI 1.69-2.67,I²=30.4%),无复发生存2.45(95%CI 1.52-3.95,I²=0.0%)。
核心结论
- 早期肺腺癌无磨玻璃影(即实性结节)与术后生存更差相关,人工智能评估及多项敏感性分析结果一致。
- 作者认为下一版分期系统对临床T分期的划分有改进空间。
研究设计与样本
- 单中心回顾性队列研究,纳入612例临床I期肺腺癌患者,采用多因素Cox回归分析磨玻璃影的预后价值。
- 采用商业人工智能软件作为第二读者判断磨玻璃影是否存在,主要终点为无复发生存和肺癌特异性生存。
- Meta分析系统检索Embase和OVID-MEDLINE截至2021年12月30日、基于第八版分期系统的研究,共纳入13项研究12080例患者。
- Meta分析采用多水平随机效应模型计算实性结节(无磨玻璃影)对各终点的汇总风险比。
关键影像表现/征象
- 术前胸部CT上病灶表现为实性结节,即无磨玻璃影成分。
诊断标准与关键数值
- 单中心队列:实性结节(无磨玻璃影)对无复发生存的校正HR为1.98(95%CI 1.17-3.51,p=0.01)。
- 单中心队列:实性结节(无磨玻璃影)对肺癌特异性生存的校正HR为1.937(95%CI 1.002-4.065,p=0.049)。
- 人工智能评估的实性结节:无复发生存校正HR 1.94(p=0.01),肺癌特异性生存校正HR 1.93(p=0.04)。
- Meta分析:实性结节对总生存的汇总HR为2.13(95%CI 1.69-2.67,I²=30.4%)。
- Meta分析:实性结节对无复发生存的汇总HR为2.45(95%CI 1.52-3.95,I²=0.0%),对无复发生存期的汇总HR为2.50(95%CI 1.28-4.91,I²=30.6%)。
临床应用与阅片要点
- 术前胸部CT判读时,对早期肺腺癌应关注磨玻璃影是否存在,实性结节(无磨玻璃影)提示术后生存更差。
- 可参考人工智能软件辅助判断磨玻璃影是否存在,其结果与人工评估结论一致。
- 作者认为下一版分期系统对临床T分期的划分有改进空间。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The prognostic value of ground-glass opacity at preoperative chest CT scans in early-stage lung adenocarcinomas is a matter of debate. We aimed to clarify the existing evidence through a single-center, retrospective cohort study and to quantitatively summarize the body of literature by conducting a meta-analysis.
METHODS: In a retrospective cohort study, patients with clinical stage I lung adenocarcinoma were identified, and the prognostic value of ground-glass opacity was analyzed using multivariable Cox regression. Commercial artificial intelligence software was adopted as the second reader for the presence of ground-glass opacity. The primary end points were freedom from recurrence (FFR) and lung cancer-specific survival (LCSS). In a meta-analysis, we systematically searched Embase and OVID-MEDLINE up to December 30, 2021, for the studies based on the eighth-edition staging system. The pooled hazard ratios (HRs) of solid nodules (i.e., absence of ground-glass opacity) for various end points were calculated with a multi-level random effects model.
RESULTS: In a cohort of 612 patients, solid nodules were associated with worse outcomes for FFR (adjusted HR, 1.98; 95% CI: 1.17-3.51; p = 0.01) and LCSS (adjusted HR, 1.937; 95% CI: 1.002-4.065; p = 0.049). The artificial intelligence assessment and multiple sensitivity analyses revealed consistent results. The meta-analysis included 13 studies with 12,080 patients. The pooled HR of solid nodules was 2.13 (95% CI: 1.69-2.67; I2 = 30.4%) for overall survival, 2.45 (95% CI: 1.52-3.95; I2 = 0.0%) for FFR, and 2.50 (95% CI: 1.28-4.91; I2 = 30.6%) for recurrence-free survival.
CONCLUSIONS: The absence of ground-glass opacity in early-stage lung adenocarcinomas is associated with worse postoperative survival.
CLINICAL RELEVANCE STATEMENT: Early-stage lung adenocarcinomas manifesting as solid nodules at preoperative chest CT, which indicates the absence of ground-glass opacity, were associated with poor postoperative survival. There is room for improvement of the clinical T categorization in the next edition staging system.
KEY POINTS: • In a retrospective study of 612 patients with stage I lung adenocarcinoma, solid nodules were associated with shorter freedom from recurrence (adjusted hazard ratio [HR], 1.98; p = 0.01) and lung cancer-specific survival (adjusted HR, 1.937; p = 0.049). • Artificial intelligence-assessed solid nodules also showed worse prognosis (adjusted HR for freedom from recurrence, 1.94 [p = 0.01]; adjusted HR for lung cancer-specific survival, 1.93 [p = 0.04]). • In meta-analyses, the solid nodules were associated with shorter freedom from recurrence (HR, 2.45) and shorter overall survival (HR, 2.13).
引用
- Lee JH, Choi Y, Hong H, et al. Prognostic value of CT-defined ground-glass opacity in early-stage lung adenocarcinomas: a single-center study and meta-analysis. Eur Radiol. 2023. PMID: 37650971. doi:10.1007/s00330-023-10160-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。